Results 91 to 100 of about 32,676 (224)

Rivaroxaban vs Dalteparin in Cancer-Associated Thromboembolism

, 2022
International audienceBackground: Direct oral anticoagulants (DOACs) are an alternative to low-molecular-weight heparin for treating cancer-associated VTE.Research question: Is rivaroxaban as efficient and safe as dalteparin to treat patients with cancer-
Boulon, Carine, Roy, Pierre-Marie, Constans, Joel, Elias, Antoine, Modéliar Rémond, Santhi Samy, Timor-David, Miruna, Jandot, Maud, Meyer, Guy, Aegerter, Philippe, Elias, Marie, Aquilanti, Sandro, Ray, Valérie, Dinut, Aurelia, Messas, Emmanuel, Mahé, Isabelle, Henni, Samir, Zenati, Nora, Charles-Nelson, Anaïs, Loffroy, Romaric, Planquette, Benjamin, Brebion, Nicolas, Delluc, Aurélien, Laneau, Christine, Grange, Claire, Imbert, Bernard, Brisot, Dominique, Plaisance, Ludovic, Le Moigne, Emmanuelle, Le Mao, Raphael, Laporte, Silvy, Bura-Rivière, Alessandra, Acassat, Sandrine, Emmerich, Joseph, Bertoletti, Laurent, Chatellier, Gilles, Sanchez, Olivier, Poénou, Géraldine, Pernod, Gilles, Revel, Marie-Pierre, Timar-David, Miruna, Girard, Philippe, Mismetti, Patrick, Burnod, Alexis, Couturaud, Francis, Sevestre, Marie Antoinette, Decousus, Hervé, Moumneh, Thomas, Hoffmann, Clément, Falvo, Nicolas   +48 more
core   +1 more source

Transformative Advances in Vascular Surgery: Five Decades of Innovation in the Management of Aortic, Carotid, and Peripheral Arterial Disease

World Journal of Surgery, EarlyView.
Ghaleb A. Darwazeh, William Q. Duong, Ramola M. Panchal, Ahmed M. Abou‐Zamzam   +3 more
wiley   +1 more source

Branch retinal artery occlusion due to patent foramen ovale in a teenager

Experimental Physiology, EarlyView.
Abstract This report demonstrates the diagnostic evaluation and clinical management of a 16‐year‐old girl who developed branch retinal artery occlusion secondary to patent foramen ovale. The goal is to increase awareness of this rare presentation in adolescents among clinicians, with a summary of the important clinical features, multimodal imaging ...
Jie Zu, Fang Fan, Jiayao Wang, Jianmin Wang, Zhiyang Jia   +4 more
wiley   +1 more source

Effects of Verapamil and Diltiazem on the Pharmacokinetics and Pharmacodynamics of Rivaroxaban

Pharmaceutics, 2019
Concomitant use of rivaroxaban with non-dihydropyridine calcium channel blockers (non-DHPs) might lead to an increase of systemic rivaroxaban exposure and anticoagulant effects in relation to the inhibition of metabolic enzymes and/or transporters by non-
Minsoo Kim, Heebin Son, Keumhan Noh, Eunyoung Kim, Beom Soo Shin, Wonku Kang   +5 more
doaj   +1 more source

Study of binding interaction of rivaroxaban with bovine serum albumin using multi-spectroscopic and molecular docking approach

Chemistry Central Journal, 2017
Background Rivaroxaban is a direct inhibitor of coagulation factor Xa and is used for venous thromboembolic disorders. The rivaroxaban interaction with BSA was studied to understand its PK and PD (pharmacokinetics and pharmacokinetics) properties.
Tanveer A. Wani, Haitham AlRabiah, Ahmed H. Bakheit, Mohd Abul Kalam, Seema Zargar   +4 more
doaj   +1 more source

Use of andexanet alfa: A British Society for Haematology position statement

British Journal of Haematology, EarlyView.
Richard J. Buka, Deepa J. Arachchillage, Catherine N. Bagot, Gary Benson, Charlotte A. Bradbury, Nicola Curry, Beverley J. Hunt, David J. Sutton, Mari R. Thomas, John Paul Westwood, Karen Breen   +10 more
wiley   +1 more source

Cardiorenal Outcomes of Dapagliflozin vs. Empagliflozin in Advanced Chronic Kidney Disease and Diabetes

Clinical Pharmacology &Therapeutics, Volume 120, Issue 1, Page 168-177, July 2026.
Target trial emulation of a multi‐institutional electronic health record network showed comparable cardiorenal effectiveness and safety of dapagliflozin versus empagliflozin in adults with type 2 diabetes and advanced‐stage chronic kidney disease.
Shih‐Hsuan Lin, Jia‐Jin Chen, Ching‐Chung Hsiao, Yu‐Wei Fang, Meng‐Ting Chen, Ming‐Hsien Tsai, Huang‐Yu Yang   +6 more
wiley   +1 more source

Cost-effectiveness of edoxaban versus rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) in the US

, 2016
Jeffrey D Miller,1 Xin Ye,2 Gregory M Lenhart,1 Amanda M Farr,1 Oth V Tran,1 W Jackie Kwong,2 Elizabeth A Magnuson,3 William S Weintraub41Truven Health Analytics Inc, Cambridge, MA, 2Daiichi Sankyo Inc, Parsippany, NJ, 3St Luke Mid-America Heart ...
Miller JD, Tran OV, Kwong WJ, Farr AM, Magnuson EA, Weintraub WS, Ye X, Lenhart GM   +7 more
core  

Rivaroxaban for thromboprophylaxis after hospitalization for medical illness

, 2018
BACKGROUND Patients who are hospitalized for medical illness remain at risk for venous thromboembolism after discharge, but the role of extended thromboprophylaxis in the treatment of such patients is a subject of controversy. METHODS In this randomized,
Spyropoulos, AC, Steg, PG, Maynard, GA, Suh, E, Ageno, W, Albers, GW, Barnathan, ES, Hiatt, WR, Weitz, JI, Halperin, JL, Elliott, CG, Spiro, TE, Raskob, GE, Sabet, A, et al.   +14 more
core   +1 more source

Diagnostic Impact of Liver Biopsy Among Antinuclear Antibody Positive Individuals With Mild Liver Enzyme Elevation

Alimentary Pharmacology &Therapeutics, Volume 64, Issue 1, Page 103-111, July 2026.
In ANA‐positive patients with suspected autoimmune hepatitis (AIH), liver biopsy rarely altered therapeutic management when alanine aminotransferase (ALT) was below 101 U/L and cirrhosis was absent. These findings suggest that biopsy may be safely deferred in this low‐risk group.
David Mehdi Asgher Niazi, Alphonse Charbel, Jan Pfeiffenberger, Uta Merle, Jessica Seessle, Theresa Wenz, Christa Flechtenmacher, Patrick Michl, Conrad Rauber   +8 more
wiley   +1 more source